Appendix 1
Register of Interests Form for use by ADTC and its subgroups

Committee members are required to complete this on an annual basis. It should also be updated throughout the year if required, if, and as soon as circumstances change.

<table>
<thead>
<tr>
<th>Name of the individual and the position held in NHS Lothian</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**What is the nature of the interest being declared?**

*Please refer to* [NHS Lothian Procedures and Guidance for Applying the Principles of Good Business Conduct](#) *procedures and guidance for good business conduct and also to the definitions provided below.*

| Personal specific: | |
| Non-personal specific: | |
| Non-personal non-specific: | |

I declare that the information I have given is correct and complete.

I understand that if I knowingly provide false information this may result in disciplinary action and I may be liable for prosecution and civil recovery proceedings.

I understand this form is a public record, and it will be made available for audit or other inspection, or disclosure under the Freedom of Information Act.

| Name | |
| Signature | |
| Date | |
Definitions of declared interests

The following is intended as a guide to the kinds of interest which should be declared. **It should be noted that if individuals have interests not specified in these notes but which they believe could be regarded as influencing their advice they should declare them.** Individual interests should be declared and examples are detailed below. It should also be noted that, in line with Standing Financial Instructions, the interests of a spouse/partner/cohabitee or close relative should also be declared, if known.

**Personal interests**

A personal interest involves payment to the individual personally, for example:

- Consultancies - any consultancy, directorship, position in or work which attracts regular or occasional payments in cash or kind.
- Fee-paid work - any work commissioned by the pharmaceutical industry for which the member is paid in cash or kind.
- Shareholdings - any shareholding in or other beneficial interest in shares of the pharmaceutical industry. This does not include shareholdings through unit trusts or similar arrangements where the member has no influence or financial management.

If a clinical expert is aware that a product under consideration is or may become a competitor of a product manufactured, sold or supplied by a company in which the expert has a current personal interest, he or she should declare an interest in the company marketing the rival product. (as per Declarations of Interest. Scottish Medicines Consortium (SMC). August 2014.)

**Personal specific interests**

A personal specific interest involves payments to an individual who has worked at any time on the product under consideration, or a direct comparator, and has personally received payment for that work, in any form, from the pharmaceutical industry.

Clinical experts should declare a personal specific interest if he or she has at any time worked on the product under consideration and has personally received payment for that work, in any form, from the pharmaceutical industry. Experts should also declare a personal specific interest if he or she has participated on an Advisory Board arranged by the pharmaceutical company. If the interest is no longer current (last three years), the expert may declare it as a lapsed personal specific interest. (Note that a personal specific interest as a result of significant involvement in the development of a product, e.g. Chief Investigator or Co-Chief Investigator of a clinical trial, or through authorship of a core publication on the product, never lapses). (as per Declarations of Interest. Scottish Medicines Consortium (SMC). August 2014.)

**Personal non-specific interests**

A personal non-specific interest involves a payment to an individual from the pharmaceutical company concerned which does not relate specifically to the product under discussion.

Clinical experts should declare a personal non-specific interest if he or she has a current personal interest in the pharmaceutical company concerned which does not relate specifically to the product under consideration. (as per Declarations of Interest. Scottish Medicines Consortium (SMC). August 2014.)
**Non-personal interests**
A non-personal interest involves payment which benefits a department for which an individual is responsible, but is not received by the individual personally, for example:
- Fellowships – the holding of a fellowship endowed by a pharmaceutical industry.
- Support by the pharmaceutical industry – any payment, other support or sponsorship by the pharmaceutical industry which does not convey any pecuniary or material benefit to a member personally but which does benefit his/her position or department.

Individuals are under no obligation to seek out knowledge of work done for or on behalf of the pharmaceutical industry within departments for which they are responsible if they would not normally expect to be informed.

**Non-personal specific interests**
A non-personal specific interest refers to payments to the individual's department, which has at any time worked on the product.

*Clinical experts should declare a non-personal specific interest if he or she is aware that the department for which he or she is responsible has at any time worked on the product but the expert has not personally received payment in any form from the pharmaceutical industry for the work done. (as per Declarations of Interest. Scottish Medicines Consortium (SMC). August 2014.)*

**Non-personal non-specific interests**
A non-personal non-specific interest refers to a department which is currently receiving payments from a pharmaceutical company concerned which does not relate specifically to the product under discussion.

*Clinical experts should declare a non-personal, non-specific interest if he or she is aware that the department for which he or she is responsible is currently receiving payment from the pharmaceutical company concerned which does not relate specifically to the product under consideration. (as per Declarations of Interest. Scottish Medicines Consortium (SMC). August 2014.)*